Drug Profile

TMB 370

Alternative Names: 10E8.4/iMab Bispecific Antibody; TMB Bispecific - Taimed biologics; TMB-370; TMB-Bispecific

Latest Information Update: 15 Mar 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Aaron Diamond AIDS Research Center
Class Antiretrovirals; Bispecific antibodies
Mechanism of Action Virus internalisation inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Suspended HIV infections

Most Recent Events

03 Mar 2022 Suspended - Phase-I for HIV infections in Taiwan (SC)
05 Apr 2019 Phase-I clinical trials in HIV infections in Taiwan (SC) ( NCT03875209)
30 Jun 2018 Preclinical trials in HIV infections in Taiwan (SC) before April 2019

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com